By Jennifer Couzin-FrankelSep. 13, 2019 , 5:15 PM After 8 hours of contentious discussion, an advisory committee to the U.S. Food and Drug Administration (FDA) today endorsed the effectiveness of a first-of-its-kind peanut allergy treatment. By a seven-to-two vote, the panel concluded that the treatment, known as AR101, can reduce allergic reactions from accidental exposure to… Read More »
It’s 2019, and you can no longer throw an airbrushed model on a billboard and call it a beauty campaign. Spurned by a culture that’s redefining what beauty standards look like, more and more brands have decided to show “real people” in their advertisements. A groundbreaking new example: Skin-care brand Blume‘s Celebrate Skin campaign takes… Read More »
So you’ve got health insurance but can’t afford the deductibles? You’re not alone. Photo: Mario Villafuerte/Getty Images For most of this century, the big U.S. health-care policy issue has been providing insurance to the uninsured, including the uninsurable people with expensive health conditions. Yes, the majority of non-elderly Americans covered by employer-based insurance were affected… Read More »
The US Food and Drug Administration (FDA) has expanded the label of non-invasive vagus nerve stimulator product gammaCore, from electroCore, Inc, to include adjunctive use in preventing cluster headaches in adult patients. The device, which was previously approved for the treatment of pain associated with migraines and cluster headaches, is a twice-daily self-administered treatment that provides… Read More »